Shots:
- Incyte to receive $35M up front & is eligible to receive an additional ~$82.5M as development, regulatory & commercial milestones along with royalties. The collaboration will accelerate the development of tafasitama in China
- InnoCare to obtain rights to develop & exclusively commercialize tafasitamab in hematology & oncology in mainland China, Hong Kong, Macau & Taiwan
- Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb. In Jun’21, EMA’s CHMP has issued a positive opinion recommending CMA of tafasitamab + lenalidomide for r/r DLBCL who are not eligible for ASCT while EC is currently reviewed CHMP opinion to grant marketing authorization in EU
Click here to read full press release/ article | Ref: Businesswire | Image: List23
The post Incyte Signs a License Agreement with InnoCare to Develop and Commercialize Tafasitamab in Greater China first appeared on PharmaShots.
